CRSP - ***Guide to the First Ever FDA CRISPR Approval Expected this Year by CRISPR & Vertex (XDNA ETF Companies)
APR 21, 2023 2:25PM EDT
Introduction
While being a newer technology, there are several publicly tradeable companies utilizing the power of CRISPR gene editing, base editing, and prime editing in the Kelly CRISPR & Gene Editing Technology ETF (Nasdaq: XDNA). Two of the XDNA companies are about to make history with potentially the first ever commercially available CRISPR technology.
***First FDA Approved Treatment - Major Milestone for the CRISPR Revolution: XDNA companies, CRISPR Therapeutics, 12.18%, and Vertex Pharmaceuticals, 1.56%, are anticipated to get the first ever U.S.-marketed treatment based on CRISPR this year for their Exa-cel therapeutic (data as of April 18, 2023).
CONTRIBUTOR
Kelly Intelligence
PUBLISHED
